It is unclear which impact nuclear ErbB2 expression in HCC has on tumor behavior and whether nuclear localized ErbB2 could be therapeutically targeted by trastuzumab and other ErbB2-directing molecules. This evidence concerns the gene ERBB2 and neoplasm.